Advertisement

Topics

MOLOGEN AG: First combination data of TLR9 agonists EnanDIM® with checkpoint inhibitor in preclinical tumor models

05:24 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonists EnanDIM® with a checkpoint inhibitor. EnanDIM® is a new family of TLR...

Other Sources for this Article

MOLOGEN AG
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

NEXT ARTICLE

More From BioPortfolio on "MOLOGEN AG: First combination data of TLR9 agonists EnanDIM® with checkpoint inhibitor in preclinical tumor models"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...